A new Mayo Clinic study found that two particular enzymes were elevated in patients with progressive multiple sclerosis (MS). The levels of these enzymes also were associated with the patients’ levels of disability. This gives researchers new hope in developing a therapy for patients with progressive MS.
To help distinguish between the types of MS and identify a therapeutic target for progressive MS, a team of Mayo Clinic researchers studied five different Kallikreins, or secreted enzymes, in patients with MS. The team tested the level of each Kallikrein in the blood of 35 patients with MS and 62 healthy patients. They found that Kallikrein 1 and Kallikrein 6 were significantly elevated in patients with progressive MS. Additionally, the higher the level of Kallikrein 1, the higher the patient’s expanded disability status score. The Mayo Clinic team also looked at the effects of these enzymes on neurons isolated from the brains of mice and found that both Kallikrein 1 and Kallikrein 6 caused significant loss of neurons and injury to axons.
“We will continue to study how Kallikrein 1 and Kallikrein 6, either separately or together, play roles in neuron injury and how it occurs in patients with progressive MS,” says Isobel Scarisbrick, Ph.D., a Mayo Clinic neuroscientist and a lead author of this study. “Eventually, we hope to determine a way to target these enzymes with therapies that will benefit patients with progressive MS.”
This study was funded by a grant from the National Multiple Sclerosis Society and the Craig H. Neilsen Foundation. It was presented at the American Neurological Association annual meeting in Salt Lake City, on Sept. 23, 2008.
We need help
Hello, I would like to know if there is any further update on this subject Progressive Multiple Sclerosis: Potential New Therapeutic Target in developing a therapy for patients with two particular enzymes were elevated in patients with progressive MS since sept 2008?
Thank you for your question on multiple sclerosis. We have sent your question on to Dr. Scarisbrick.
I’d also like further information about this study and where Dr. Scarisbrick is now in the process. Thank you.
Thank you for your comments. This research is ongoing. Dr. Scarisbrick and her team are currently verifying the findings in additional patient samples. They also are conducting additional studies to look at the functional significance of how enzymes affect neurons. When additional research is published, we will be sure to update the original blog post.
This is promising news, but we need more info about treatment possibilities to block these enzymes.
MArch 2011 What is the update on treatment possibilities to block these enzymes?
what is the lastest thing avaible for ms patients
Check our these links for informationon multiple sclerosis:
http://www.mayoclinic.org/multiple-sclerosis/
http://mayoresearch.mayo.edu/mayo/research/multiple-sclerosis-center/understanding-genetic-determinants.cfm
2008,,,3 years ago anything new????…… i see NO new news for PPMS and its 2011…:( iam scared..we rely sooo much on other people to figure this out for us or just to help munecagirl22@yahoo.com